about
Population pharmacokinetics of fluconazole in young infants.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Medication errors made by health care professionals. Analysis of the Finnish Poison Information Centre data between 2000 and 2007.Position paper update: gastric lavage for gastrointestinal decontamination.Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia.Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007.Evaluation of Antimicrobial Therapy of Blood Culture Positive Healthcare-Associated Infections in Children.A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A.Realities of paediatric pharmacotherapy in the developing world.The status of paediatric medicines initiatives around the world--What has happened and what has not?Position paper update: ipecac syrup for gastrointestinal decontamination.Limited impact of EU paediatric regulation on Finnish clinical trials highlights need for Nordic collaboration.Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients.How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.Off-label use of antimicrobials in neonates in a tertiary children's hospital.Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial.Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study.Virulence genes of Aeromonas isolates, bacterial endotoxins and cyanobacterial toxins from recreational water samples associated with human health symptoms.First report of saxitoxin in Finnish lakes and possible associated effects on human health.Age differences in trimethoprim pharmacokinetics: need for revised dosing in children?[Clinicopathological conference LXXII. Fever, lung changes, intestinal perforation and peripheral cyanosis in an infant]Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism.Disopyramide and breast feeding.Trimethoprim in the treatment of acute urinary tract infections in children.Determination of trimethoprim in pediatric samples by high-performance liquid chromatography.[Household chemicals causing sudden poisoning].[Treatment of paracetamol intoxication. Correctly given antidote treatment will prevent liver damage].Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients.Fatal poisonings in Finland during the years 2004-2009.Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life.Trimethoprim pharmacokinetics in children with renal insufficiency.[Risk of arrhythmia in long-acting H1-selective antihistaminics poisoning]Can we get the necessary clinical trials in children and avoid the unnecessary ones?First-order alcohol elimination in severe alcohol intoxication in an adolescent: a case report.Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.Global aspects of drug development.Migraine attacks and sleep in children.Reflection: medicines for children--science alone is not enough.
P50
Q30439710-D176C8F9-F8FD-4AF6-A482-7B9EA4EA4A60Q30844731-6FCAA04E-7FBA-47F1-89FF-84B286DE248FQ31157017-7A66CD3D-32C9-41E4-8544-CBB86F284A04Q34648455-7004E057-34F0-4258-8EA0-0EBEB2E0F446Q34734294-6619797C-8233-487F-946C-59065362F4ADQ34996953-19BCFA2F-5955-45EB-9B74-96DD599FBFC9Q35833287-21D2C893-A207-4803-B7F3-906D823ECAF6Q37219058-2F9BB985-35AF-4358-82B0-B015A40F2EE9Q37858274-9655DAA0-5EA7-4FC4-9308-EC2908E1AA41Q37898039-5016BF86-40FE-45BC-82E6-0ACACE58FA92Q38081211-54E038CA-CE81-4D1E-A7AA-C0D0B9D19DC8Q38124376-4C4E5C0F-B382-4494-AC13-B07FF29D3EE8Q38289616-57F4FB9D-3E93-473D-B0C0-09FB7748BEEBQ38965300-7F009332-80D9-4723-AD92-0C56DECD7DE5Q39013368-9F95E61C-B7CA-4D88-ACAA-12E60E539324Q39382884-5DF2E43C-D325-439F-AB2E-7D1C02E25079Q39456945-2DCB2BE9-B9CF-4FD9-B66C-0255C37BA438Q39459815-A85A0DAA-05FF-4316-A99F-E38FE190BE1AQ40307036-08107241-507F-43A4-B174-03EA7C52CF42Q40508598-CAF39B69-38D9-4CAA-82D0-BCDC195579D3Q40798852-52E0508C-378D-4275-9B8F-6B3EB9237907Q40847653-C8561E24-73CC-4D7D-96C6-88DC96625FBBQ42283823-0C3545AF-BCBD-4A08-A3CC-8D938CC4AC74Q43182515-527C0389-8E62-4D1C-A51C-E36494F4F730Q43240498-7EAC5574-B79C-49C7-AEF4-059551AA2F47Q43769900-432D5123-2AA6-41BB-99DE-1103230A7579Q43826209-FA1EF9DE-7451-47B3-AB6B-4661E06F37DBQ43932191-71D535DA-4104-4FDA-91C8-D307AC814DB8Q44135310-BF734FEA-93B6-4889-9DAE-64CA0BBCCCECQ44373816-F82E9AB6-76BF-4781-8B6B-89BA5FF25139Q44510597-441A516F-0336-4B61-9F7F-E752E3F8B9EDQ44700606-0D51DA90-501A-42F6-9161-E98F54245436Q44944414-3E9814FE-56C4-47D1-9CA5-AE77B9598F5FQ45075818-BDAFEF9D-13D8-4F39-B32E-0711C5233B8BQ45971835-956D8503-B89E-4CE3-8B5B-2F7811A09A81Q46223455-7A338A97-948E-4A3B-BDCB-EF862FCD7256Q46809845-C3C2D6D7-5B2C-4F53-8735-8A1D1858B704Q47269899-DD1558D3-F1CF-4E60-8BA9-8FC86B9AB75DQ48710181-D72BC1F1-8A92-4943-A8EE-BF949A0B6D16Q48958057-B0C88C91-4032-4F41-9075-E80800DD8E8C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kalle Hoppu
@ast
Kalle Hoppu
@en
Kalle Hoppu
@es
Kalle Hoppu
@nl
Kalle Hoppu
@sl
type
label
Kalle Hoppu
@ast
Kalle Hoppu
@en
Kalle Hoppu
@es
Kalle Hoppu
@nl
Kalle Hoppu
@sl
altLabel
Kaarlo Hoppu
@en
prefLabel
Kalle Hoppu
@ast
Kalle Hoppu
@en
Kalle Hoppu
@es
Kalle Hoppu
@nl
Kalle Hoppu
@sl
P106
P21
P31
P496
0000-0001-6775-0453